Enanta Pharmaceuticals (NASDAQ:ENTA) Rating Reiterated by HC Wainwright

Enanta Pharmaceuticals (NASDAQ:ENTA)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a report released on Tuesday, Benzinga reports. They currently have a $48.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective would suggest a potential upside of 280.05% from the company’s current price.

Several other research firms have also recently issued reports on ENTA. StockNews.com raised Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, September 11th. Oppenheimer cut their price target on Enanta Pharmaceuticals from $30.00 to $25.00 and set a “market perform” rating on the stock in a report on Wednesday, August 9th. JPMorgan Chase & Co. downgraded Enanta Pharmaceuticals from a “neutral” rating to an “underweight” rating and set a $14.00 price objective for the company. in a research report on Wednesday, August 9th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $25.00 target price on shares of Enanta Pharmaceuticals in a report on Tuesday, August 8th. Finally, JMP Securities reduced their price objective on shares of Enanta Pharmaceuticals from $65.00 to $42.00 and set a “market outperform” rating on the stock in a report on Tuesday, August 8th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $38.50.

Enanta Pharmaceuticals Trading Down 0.8 %

ENTA opened at $12.63 on Tuesday. The firm has a market capitalization of $265.99 million, a PE ratio of -2.00 and a beta of 0.41. Enanta Pharmaceuticals has a twelve month low of $11.56 and a twelve month high of $62.06. The firm’s 50-day moving average price is $16.43 and its 200 day moving average price is $26.51.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($1.86) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.38) by $0.52. The business had revenue of $18.89 million during the quarter, compared to analyst estimates of $15.88 million. Enanta Pharmaceuticals had a negative return on equity of 46.77% and a negative net margin of 163.87%. As a group, analysts predict that Enanta Pharmaceuticals will post -7.24 earnings per share for the current fiscal year.

Institutional Trading of Enanta Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in ENTA. Tower Research Capital LLC TRC raised its stake in shares of Enanta Pharmaceuticals by 80.1% during the second quarter. Tower Research Capital LLC TRC now owns 2,026 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 901 shares during the last quarter. Royal Bank of Canada lifted its stake in shares of Enanta Pharmaceuticals by 68.7% during the second quarter. Royal Bank of Canada now owns 2,665 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 1,085 shares during the period. PNC Financial Services Group Inc. grew its position in shares of Enanta Pharmaceuticals by 146.7% in the second quarter. PNC Financial Services Group Inc. now owns 2,771 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 1,648 shares during the period. Captrust Financial Advisors grew its holdings in Enanta Pharmaceuticals by 343.8% in the first quarter. Captrust Financial Advisors now owns 852 shares of the biotechnology company’s stock valued at $61,000 after purchasing an additional 660 shares during the period. Finally, Point72 Hong Kong Ltd increased its position in Enanta Pharmaceuticals by 83.7% during the second quarter. Point72 Hong Kong Ltd now owns 1,565 shares of the biotechnology company’s stock worth $74,000 after purchasing an additional 713 shares during the last quarter. Institutional investors and hedge funds own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.